Companies/US/ABBV

ABBVIE INC.

Last · NYSE$283.52+9.165 (+3.34%)live · yahoo · 5h ago
Vol 4.20M ≈ 1.19B
Market cap$501.02B1.77B sh
P/E · TTM80.1fwd 17.5 · eps 3.54
Beta0.23vs S&P 500
Div yield2.49%annual · TTM
52w range
$190.75$285.40
Volume4.2Msession

Issuer

Legal nameABBVIE INC.
HQUnited States (US)
ListingUS ABBV
ISINUS00287Y1091
SectorHealthcare
IndustryDrugs (Pharmaceutical)
SIC2834
CurrencyUSD
Entity registrysec:0001551152
CIK0001551152
LinkedIn
Employees57,000
AddressAbbVie, Inc. 1 North Waukegan Road 60064-6400, North Chicago +847 932 7900
Headline financial metrics
Revenue$64.4B
Operating income$16.9B
Net income$6.3B
Free cash flow$18.2B
Operating margin26.2%
Net margin9.7%
PeriodTTM 2026-06-30
Loading chart…

OpenFilings analyst

Our analyst

10-K · 2026-02-20

From latest 10-K · 2026-02-20

  • Revenue Growth
  • Skyrizi Rinvoq Concentration
  • Medicare Price Setting
  • Patent Exclusivity
  • Biosimilar Risk
  • Debt Leverage
  • Pipeline Execution

Red flags

  • Skyrizi and Rinvoq together generated approximately 42% of 2025 net revenue, creating material concentration in two immunology products.
  • Total long-term debt and finance lease obligations were $65.0 billion at year-end 2025, including $6.1 billion due within one year, versus $5.2 billion of cash and equivalents.
  • AbbVie recorded $6.5 billion of contingent-consideration fair-value expense, $7.4 billion of intangible amortization and $847 million of intangible impairment in 2025; contingent consideration liabilities were $25.4 billion at year-end.
  • Imbruvica, Vraylar, Linzess and Botox are scheduled for Medicare government price-setting beginning in 2026, 2027, 2027 and 2028, respectively, potentially accelerating revenue erosion before patent expiry.
  • 2025 diluted EPS was only $2.36, down from $2.39 in 2024 and $2.72 in 2023, despite 9% revenue growth, reflecting the burden of amortization, financing and acquisition-related items.

Upcoming earnings

1 event
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$3.79
Est. revenue
17.3B

Earnings transcripts

1 recent

Press & signals

3 of 8 recent
  • Satelight

    Fantasy M&A: the recipe for a European champion

  • Satelight

    Retrieval-grounded robot program generation and simulation-based correction via Model Context Protocol

  • Satelight

    Psychedelic drugs are going mainstream

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
2026-09-302026-10-020
2026-09-302026-10-020
2026-08-182026-08-180
2026-08-142026-08-180